HMBD-501 is a HER3-targeted ADC with a differentiated mechanism of action, engineered by Hummingbird Bioscience for optimal safety and efficacy SINGAPORE, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Hummingbird ...
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in ...
SINGAPORE, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for diseases with significant unmet need, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results